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Abstract 
Introduction: Resistin is a pro-inflammatory adipokine that increases after brain injury (trauma, bleeding) and may 
initiate an inflammatory response. Resistin was found increased in deceased, brain dead organ donors (DBD) and 
correlated with delayed graft function after kidney transplantation. The kinetics of resistin during brain death (BD), its 
impact on the inflammatory response and the influence of several donor variables on resistin levels are still unknown.
Methods: Resistin along with a panel of Th1/Th2 cytokines [interferon (IFN)-gamma, interleukin (IL)-1beta, IL-2, IL-6, 
IL-8, IL10, IL-12, IL-13 and tumor necrosis factor (TNF)] was analyzed in 36 DBDs after the diagnosis of BD and before 
organ procurement and in 12 living kidney donors (LD). The cytokine levels and resistin were analyzed in relation to 
donor parameters including cause of death, donors’ age and steroid treatment.
Results: Resistin levels were higher in DBDs both at BD diagnosis and before organ procurement compared to 
LD (p < 0.001). DBDs had significantly increased IL-1beta, IL-6, IL-8, IL-10 and TNF levels at both time points com-
pared with LD. In DBDs, resistin at BD diagnosis correlated positively with IL-1beta (rs 0.468, p = 0.007), IL-6 (rs 0.511, 
p = 0.002), IL-10 (rs 0.372, p = 0.028), IL-12 (rs 0.398, p = 0.024), IL-13 (rs 0.397, p = 0.030) and TNF (rs 0.427, p = 0.011) 
at procurement. The cause of death, age over 60 and steroid treatment during BD did not affect resistin levels. How-
ever, steroid treatment significantly decreased pro-inflammatory cytokines IL-1beta, IL-8, TNF and IFN-gamma at the 
time of organ procurement.
Conclusions: Resistin is increased early in DBDs, remains increased throughout the period of BD and correlates 
strongly with pro-inflammatory mediators. Resistin level, in contrast to cytokines, is not affected by steroid treatment. 
Resistin increase is related to the BD but is not influenced by age or cause of death. Resistin may be one of the initial 
triggers for the systemic inflammatory activation seen in DBDs.
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Background
Deceased brain dead (DBD) organ donors regularly 
manifest a pronounced inflammatory state resembling 
the systemic inflammatory response syndrome (SIRS) 
but its initiating stimuli still remain incompletely known. 
The increased circulating pro-inflammatory mediators 
(cytokines, chemokines) released before or during the 
period between the declaration of brain death and organ 
procurement lead to an increased apoptosis, inflamma-
tory activation and tissue injury in various organs [1, 
2]. These changes increase the susceptibility for both 
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ischemia–reperfusion injury as well as rejection, and 
may contribute to the inferior results recorded following 
transplantation of organs from deceased donors as com-
pared with those obtained from healthy, living donors [3, 
4].
Resistin, a protein initially described as an adipocyte-
secreted peptide in rodents and postulated to contribute 
to insulin resistance, has recently been shown to play an 
important role in the various inflammatory conditions 
[5]. In humans, resistin expression on primary adipo-
cytes is low whereas it is highly expressed on the cells of 
monocyte-macrophage lineage [5, 6]. Resistin has several 
features in common with pro-inflammatory cytokines 
[7, 8]. It promotes inflammation through induction of 
other cytokines and the expression of resistin itself is 
strongly up-regulated on the peripheral blood mononu-
clear cells in response to stimulation with pro-inflam-
matory cytokines such as IL-6, TNF-α and IL-1β and 
LPS [7, 9]. In humans, elevated levels of resistin are fre-
quently found in association with autoimmune diseases 
and inflammation [5]. Resistin has been implicated in 
obesity, diabetes, and atherosclerosis, cardiovascular and 
rheumatic diseases [10–13]. Increased resistin levels have 
also been reported in patients with intracerebral hemor-
rhage and head trauma [14, 15]. Importantly, we recently 
showed that increased resistin level measured in brain 
dead organ donors was associated with delayed graft 
function and need for dialysis in kidney allograft recipi-
ents after transplantation of kidneys from these donors 
[16]. However, it is unclear whether higher resistin con-
centrations are present already at the time of diagnosis of 
brain death and whether resistin further increases dur-
ing the period between the declaration of BD and organ 
procurement. Since resistin is able to initiate endothelial 
activation [17], and induce a pro-inflammatory cytokine 
response [7], it could commence and further amplify the 
systemic inflammatory response syndrome and serve as a 
potential target of the therapy. Therefore, it is imperative 
to understand the underlying mechanisms and identify 
therapeutic interventions that may curb the development 
of the systemic inflammation in the DBD and limit its 
consequences on the transplantable organs.
Here, we studied the kinetics of resistin in DBD organ 
donors between the declaration of brain death and organ 
procurement, the relationship of resistin with cytokines, 




Plasma samples were obtained from 36 DBD organ 
donors from our procurement area between Decem-
ber 2011 and March 2014. The donors (or next of kin) 
previously had consented for blood/tissue donation 
for the purpose of medical research. The study was 
approved by the Ethical Committee of the University of 
Gothenburg.
Blood was drawn in ethylene-diamine-tetra-acetic 
acid (EDTA) containing tubes from DBD donors on the 
intensive care unit at the time of diagnosis of brain death 
(acceptance as organ donors) and in the operation room 
immediately before the start of the organ procurement 
procedure. The blood was stored at 4°C until centrifu-
gation. Following centrifugation at 2000  rpm for 5  min 
plasma was recovered, aliquoted and stored at −80°C 
until analysis. Donor information regarding age, gender 
and cause of death were retrieved. Methylprednisolone 
was given to all donors considered for thoracic organ 
procurement soon after the declaration of brain death 
and acceptance into donorship (15 mg/kg).
Blood samples were also obtained from healthy indi-
viduals donating a kidney for transplantation at our unit 
(i.e. living donors, LD) the day before surgery. All LD 
were informed and consented for the sampling and the 
samples were prepared as described above.
Measurement of resistin and cytokines
Resistin was measured using a colorimetric sandwich 
ELISA kit (RnD Systems, Minneapolis, MN, USA) fol-
lowing manufacturer’s instructions. The lower detection 
limit was 0.16 ng/ml for resistin. The samples also were 
analyzed for a panel of pro-inflammatory (Th1) and anti-
inflammatory (Th2) cytokines. Plasma concentrations 
of IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, 
IL-13 and TNF were determined by the electro-chemi-
luminescence multiplex system Sector 2400 imager from 
Meso Scale Discovery (Gaithersburg, MD, USA).
Statistical analyses
Non-parametric statistical methods were used since all 
continuous variables from DBD as tested for Gaussian 
distribution with D’Agostino and Pearson omnibus nor-
mality test showed non-normal distribution. Kruskal–
Wallis test followed by Dunn’s multiple comparisons 
correction test was used to compare the mean rank val-
ues if three or more groups were analysed. Statistically 
significant relationships were further analyzed using the 
Mann–Whitney U test. The Wilcoxon signed rank test 
for paired samples was used to analyze the changes in 
variables between two time points. Associations between 
variables were assessed using the Spearman’s rank cor-
relation test and coefficient expressed as Spearman’s rho. 
Analyses were performed using GraphPad Prism v. 6 
(GraphPad software). Data are expressed as median and 
range, unless otherwise stated. A p value <0.05 was con-
sidered significant.
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Results
Donor characteristics
Samples were obtained from 36 DBD donors and 12 liv-
ing donors. DBD donors were significantly older than LD 
[median age 64 (range 7–79) vs 46 (34–66), respectively]. 
Table 1 summarizes the main donor characteristics.
Resistin levels in the deceased brain dead and living 
donors
Median resistin concentration in the LD group was 8 ng/
ml (range 4–12  ng/ml). In DBD donors, resistin was 
found at 4–5-fold higher concentrations than in LD at 
both time-points (p  <  0.0001). Median resistin concen-
tration at the time of diagnosis of BD and acceptance to 
the donorship was 41 (13–120) ng/ml, while its median 
concentration immediately before procurement was 
39 (9–117) (Figure  1a). No significant differences were 
observed regarding resistin levels when the DBD donors 
were stratified according to the cause of brain death 
(Figure  1b). At the diagnosis of BD, the median resistin 
concentrations in donors with cerebrovascular bleeding, 
anoxia and trauma were 36 (13–120) ng/ml, 44 (19–102) 
ng/ml and 41 (14–80) ng/ml, respectively.
The cytokine levels in the deceased brain dead and living 
donors
Serum concentrations of IL-6 and IL-10 were signifi-
cantly higher in DBD donors compared to LD at the time 
of brain death diagnosis [IL-6: 152 (4–2,513) ng/ml vs 0.6 
(0.3–5.3) ng/ml, p = 0.0001; IL-10: 2.4 (0.3–46.6) ng/ml 
vs 0.2 (0.1–0.4) ng/ml, p  =  0.004, respectively]. At the 
organ procurement, IL-6 and IL-10 levels in DBD were 
91 (3–2,760) ng/ml and 1.8 (0.3–31) ng/ml, respectively. 
The level of IL-2, IL-8, IL-12, IL-13, and TNF were sig-
nificantly higher in DBDs at the time of brain death diag-
nosis as compared to LD.
During the period of brain death, IFN-γ, IL-1β, IL-2, 
IL-8 and TNF significantly decreased and lower values 
were detected immediately before the organ procure-
ment (T2) compared with the values at the declaration of 
BD (T1). The concentration of the various Th1 and Th2 
cytokines are summarized in Figures 2 and 3.
Overall, the cytokine levels were elevated more than 2 
standard deviations above the mean level of that detected 
in LD in the majority of DBD. IFN-γ was elevated in 29%, 
IL-2 in 36%, IL-12 in 47%, IL-13 in 56%, IL-1β in 60%, 
IL-8 74%, TNF in 86%, IL-10 in 94% and IL-6 in 100% of 
DBD donors. At organ procurement, 97% of DBD donors 
had high IL-6 and IL-10 levels in relation to LD, and ele-
vated TNF was seen in 77% (Figures 2, 3).
The relationship between resistin and cytokines
At the time of BD diagnosis, a positive association was 
found between resistin and IL-1β, IL-2, IL-6, IL-12 and 
IL-13 levels. Resistin levels measured at the BD diagnosis 
correlated strongly with IL-6 (rs 0.511, p = 0.002), TNF 
(rs 0.427, p = 0.011), IL-1β (rs 0.468, p = 0.007) and mod-
erately with IL-10 (rs 0.372, p =  0.028), IL-12 (rs 0.398, 
Table 1 Donor characteristics (n = 36)
Deceased donors
 Male/Female 20/16
 Age (median, range) 64 (7–79)
 Cause of death (%)
  Cerebrovascular accident 18 (50%)
  Anoxia 12 (33%)
  Trauma 6 (17%)
  Steroid treatment (%) 21 (58%)
  Time between samplings (min) 352 (120–1,200)
Living donors (n = 12)
 Male/Female 3/9
 Age (median, range) 46 (34–66)
Figure 1 a Resistin levels in all the DBD donors at the time of the diagnosis of brain death (T1), immediately before organ procurement (T2) and in 
living kidney donors (LD). b Resistin levels at both timepoints in DBD donors divided according to the cause of death. The box plots show medians 
and interquartile range, whiskers show 5–95th percentiles; #p < 0.001; CVA cerebrovascular accident.
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p = 0.024), and IL-13 (rs 0.397, p = 0.03) at the time of 
procurement (Table 2).
The effect of steroid treatment on resistin and cytokine 
levels
The median resistin levels did not differ between DBD 
donors receiving methylprednisolone treatment (n = 24) 
or non-treated DBD donors (n = 12) at any time-point. 
However, methylprednisolone administration during 
the period between the diagnosis of brain death and 
organ procurement resulted in lower concentrations of 
donor IFN-γ, IL-1β, IL-8 and TNF at the time of organ 
procurement as compared to the levels at diagnosis. Of 
note, the levels of IFN-γ, TNF and IL-1β were signifi-
cantly lower in steroid treated BDB donors as compared 
to the levels in the non-treated DBD donors at the time 
of organ procurement (Figure  4). Also, IL-6 concentra-
tions were significantly lower in steroid treated DBD 
donors at the time of organ procurement (p < 0.05) and 
a trend towards the decrease of IL-6 levels between 
two time points was seen following steroid treatment 
(p = 0.09) (Figure 5).
Importantly, the resistin concentration at BD diagnosis 
correlated strongly with IL-1β (rs 0.672, p = 0.023), IL-2 
(rs 0.700 p = 0.016), IL-6 (rs 0.726, p = 0.011) and IL-12 
(rs, 0.697, p = 0.025) at organ procurement in the DBD 
donors that did not receive steroid treatment.
Older donors (>60) did not differ at any of the two time 
points from the younger donors with respect to resistin 
levels and the studied cytokines.
Discussion
We recently reported increased resistin at the time of 
organ procurement but it has been unclear whether 
this increase occurred in the time elapsed between 
BD diagnosis and organ donation or this increase was 
apparent at an earlier moment. The current results indi-
cate an increased plasma resistin and a robust cytokine 
response already very early in the process of organ 
donation.
Increased resistin concentration has been detected 
after the head trauma or intracerebral bleeding and it 
has been suggested that its concentration is proportional 
with the magnitude of injury [15, 18]. This increase is 
quite rapid and significant since resistin increase may 
occur in head trauma setting within 6 h [14]. We found 
similar concentrations of resistin as those reported ear-
lier after severe head trauma or intracerebral bleeding. 
However, during a median observation period range of 
2–20  h during the BD we did not observe any further 
increase suggesting that resistin increase is not a phe-
nomenon specific for the state of brain death but rather 
of the brain injury leading to the BD, independently of 
the mechanism of injury.
Figure 2 The Th1 cytokines in all the brain dead donors at the time of the diagnosis of brain death (T1) and immediately before organ procure-
ment (T2) and in living kidney donors (LD). The box plots on logarithmic scale show medians and interquartile range (IQR), whiskers show 2.5–97.5th 
percentiles. *p < 0.05; **p < 0.01, ***p < 0.001.
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Accumulating evidence supports a role of human resistin 
as a pro-inflammatory molecule. Human resistin is highly 
expressed, up-regulated and secreted from peripheral blood 
mononuclear cells (PBMC), macrophages and neutrophils 
in response to various stimuli [6, 9, 19], and in turn, acts on 
these cells and leads to enhanced inflammatory reaction 
Figure 3 The Th2 cytokines in all the brain dead donors at the time of the diagnosis of brain death (T1) and immediately before organ procure-
ment (T2) and in living kidney donors (LD). The box plots on logarithmic scale show medians and interquartile range (IQR), whiskers show 2.5–97.5th 
percentiles. *p < 0.05; ***p < 0.001.
Table 2 Resistin level at  the diagnosis of  brain death is associated with  cytokines at  the diagnosis of  brain death (T1) 
and at organ procurement (T2)
The associations were assessed with two-tailed Spearman’s rank correlation test and the correlation coefficient (rs) and p value are shown.
Cytokine T1 all donors (n = 36) T2 all donors (n = 36) T2 untreated donors (n = 12)
rs P value rs P value rs p value
IFN-gamma 0.034 0.847 0.207 0.234 0.500 0.117
IL-1 beta 0.431 0.010 0.468 0.007 0.673 0.023
IL-2 0.350 0.046 0.248 0.178 0.700 0.016
IL-4 0.129 0.505 0.318 0.114 0.667 0.049
IL-6 0.398 0.018 0.511 0.002 0.727 0.011
IL-8 0.314 0.066 0.116 0.509 0.082 0.81
IL-10 0.217 0.210 0.372 0.028 0.318 0.340
IL-12 0.444 0.009 0.398 0.024 0.697 0.025
IL-13 0.503 0.003 0.397 0.030 0.482 0.133
TNF 0.249 0.149 0.427 0.011 0.455 0.160
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through activation of intracellular signaling [20]. Although 
the receptor for resistin is still disputed [21, 22] it is shown 
that the subsequent intracellular signaling occurs mainly 
through the NF-κB pathway, the same pro-inflammatory 
pathway involved in the synthesis and secretion of numer-
ous pro-inflammatory cytokines shifting cells towards an 
inflammatory phenotype [17, 20, 23]. Resistin has been 
shown to up-regulate the expression of TNF, IL-6, IL-12 in 
PBMC and macrophages [7, 20]. In line with these findings, 
we identified strong positive correlations between the resis-
tin levels at the diagnosis of brain death and several major 
pro-inflammatory cytokines at both the first and the second 
time-point during the brain death. The correlation between 
resistin and TNF, IL-1β and IL-6 were stronger at the latter 
time-point before organ procurement.
The current results may infer a causal relationship 
between resistin and these cytokines and indirectly sug-
gest resistin as an initial stimulus for inflammatory status 
of DBDs but more work at molecular level on clinical 
samples is needed in order to establish its significance 
and biological effects. In this setting rodent models of BD 
may have a limited value as the biologic roles of resistin 
differ between rodents and humans and rodent models 
tend to have a shorter duration and more limited possi-
bilities for therapeutic interventions.
The induction of a cytokine response during BD and 
the inflammatory activation of various organs have 
earlier been reported both in experimental and clini-
cal setting [1, 24]. This systemic inflammatory response 
ultimately results in an inflammatory cascade includ-
ing complement activation, endothelial activation and 
increased pro-inflammatory mediators. All these molec-
ular events cause direct injury to the various transplant-
able organs, increase the susceptibility of the future graft 
to ischemia–reperfusion injury and may ultimately relate 
with increased recipient mortality after transplantation 
Figure 4 The effect of steroid treatment of the brain dead donors on several cytokines at the time of the diagnosis of brain death (T1) and imme-
diately before organ procurement (T2). The box plots show medians and interquartile range (IQR), whiskers show 2.5–97.5th percentiles. Grey boxes 
denote treated DBD donors whereas open boxes represent untreated DBD donors. *p < 0.05; **p < 0.01, ***p < 0.001.
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[25]. Steroid treatment has been shown to abate the levels 
of several pro-inflammatory factors both in the tissue and 
in the circulation and may improve the outcome of trans-
plantation [26, 27]. In line with these studies, we found 
lower levels of pro-inflammatory cytokines at the latter 
time-point in the DBDs treated with steroids. This sug-
gests that in spite of high levels of resistin still present in 
circulation, part of its pro-inflammatory effects may be 
alleviated by steroids.
The present report is from a single-center and has the 
characteristic limitations of any small series in which the 
low number and the heterogeneity of the donors pre-
vented further in-depth subgroup analyses and could 
have made some results prone to a type 2 error. The lack 
of information on the inflammatory response in the tis-
sues of the various transplantable organs somewhat 
restricts the interpretation of the data. According to our 
centers’ policy, biopsies are taken only after graft reperfu-
sion and hence, no tissues from earlier time-points were 
available for further analyses.
A significant strength is the collection of data from two 
time-points, allowing for certain mechanistic studies. 
Moreover, we avoided the confounding influence of the 
surgical stress on the cytokine response by performing 
the last sampling before the start of the organ procure-
ment procedure [28]. Although the DBDs studied herein 
were not consecutive and included only donors who pre-
viously consented for the research purposes, the studied 
group mirrors well the overall donor characteristics at our 
center with regard to age, gender and cause of death. Our 
single center study also has the advantage of managing 
both organ donors and transplant recipients according to 
similar protocols and routines throughout the study.
Conclusion
Our results indicate that high resistin levels were 
detected already early in DBD in the process of organ 
donation. Resistin levels remained increased throughout 
the period of brain death and correlated strongly with 
several major pro-inflammatory circulating mediators. 
Resistin level, in contrast to cytokines, was not affected 
by steroid treatment. Our observations propose resistin 
as an early potential stimulus for the systemic inflamma-
tory response seen during brain death and confirm the 
ability of methylprednisolone treatment to down-regu-
late key pro-inflammatory cytokines in DBDs.
Key messages
  • Deceased brain dead donors have greatly increased 
circulating resistin already at the time of diagnosis of 
brain death.
  • Early resistin levels correlate strongly with several 
Th1 cytokines immediately before organ procure-
ment.
  • Donor treatment with steroids alleviate the cytokine 
response in spite of high resistin levels.
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Figure 5 The effect of steroid treatment of the brain dead donors 
on interleukin-6 at the time of the diagnosis of brain death (T1) and 
immediately before organ procurement (T2). The box plots on loga-
rithmic scale show medians and interquartile range (IQR), whiskers 
show 2.5–97.5th percentiles. Grey boxes denote treated DBD donors 
whereas open boxes represent untreated DBD donors. *p < 0.05; 
**p < 0.01, ***p < 0.001.
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